Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE)
Source: View publication →
The I-PRESERVE trial demonstrated that the angiotensin II receptor blocker irbesartan did not reduce the primary composite endpoint of all-cause mortality or cardiovascular hospitalization in patients with symptomatic heart failure and preserved ejection fraction (HFpEF) compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The study confirmed that neurohumoral blockade with an angiotensin receptor blocker, similar to findings with ACE inhibitors in previous HFpEF trials, does not improve clinical outcomes in patients with HFpEF, reinforcing the need for alternative therapeutic strategies.
Historical Context
At the time of the I-PRESERVE trial, the efficacy of renin-angiotensin-aldosterone system (RAAS) inhibitors in heart failure with reduced ejection fraction (HFrEF) was well-established. However, the management of heart failure with preserved ejection fraction remained an unmet challenge, with previous trials like CHARM-Preserved and PEP-CHF also failing to demonstrate clear survival or hospitalization benefits for RAAS inhibition in this specific patient population.
Guided Discussion
High-yield insights from every perspective
Given that RAAS inhibitors like irbesartan are cornerstone therapies for reducing mortality in heart failure with reduced ejection fraction (HFrEF), what pathophysiological differences in heart failure with preserved ejection fraction (HFpEF) might explain why irbesartan failed to show a similar benefit in the I-PRESERVE trial?
Key Response
While HFrEF is characterized by progressive ventricular dilation and neurohormonal-driven adverse remodeling, HFpEF is a more heterogeneous syndrome often driven by systemic inflammation, microvascular dysfunction, and stiffening of the myocardium due to comorbidities like obesity, hypertension, and diabetes. In HFpEF, the RAAS pathway may not be the primary driver of disease progression, making isolated RAAS blockade less effective than in the dilated, high-renin state of HFrEF.
Following the neutral results of the I-PRESERVE trial, how should a clinician approach the use of ARBs like irbesartan in a patient with symptomatic HFpEF and concomitant hypertension?
Key Response
The I-PRESERVE trial indicates that irbesartan should not be prescribed for the specific purpose of reducing cardiovascular mortality or heart failure hospitalizations in HFpEF. However, because hypertension is a major contributor to HFpEF pathogenesis and a common comorbidity, ARBs remain a first-line choice for blood pressure management in these patients. The goal in HFpEF remains symptom control (diuretics) and aggressive management of underlying risk factors rather than expecting a disease-modifying mortality benefit from the ARB itself.
The I-PRESERVE trial used an LVEF cutoff of ≥45%. How does the 'neutral' result of this trial compare to later findings in the 'mildly reduced' EF range (41-49%), and how might the inclusion of this subgroup have affected the study's overall outcome?
Key Response
Later evidence (such as the PARAGON-HF and TOPCAT subgroup analyses) suggests that patients at the lower end of the 'preserved' EF spectrum (specifically 40-55%) may derive some benefit from RAAS or neprilysin inhibition. By including a broad range of truly preserved EFs where diastolic dysfunction and non-cardiac comorbidities predominate, I-PRESERVE may have diluted potential signals of benefit that exist in the heart failure with mildly reduced ejection fraction (HFmrEF) phenotype.
How did the I-PRESERVE trial challenge the then-prevalent 'class effect' assumption that evidence-based therapies for HFrEF would naturally translate to benefit in HFpEF patients?
Key Response
I-PRESERVE was a landmark 'neutral' trial that provided a sobering lesson in evidence-based medicine: it demonstrated that HFpEF is a distinct clinical entity from HFrEF. It forced the cardiology community to move away from extrapolating HFrEF data and spurred the search for HFpEF-specific mechanisms, eventually leading to the study of SGLT2 inhibitors and ARNI, which finally showed efficacy where traditional RAAS blockade alone failed.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The I-PRESERVE trial observed a lower-than-predicted annual event rate in both the treatment and placebo arms. What are the statistical implications of this lower event rate on the study's power, and what enrichment strategies could modern researchers use to avoid this issue in HFpEF trials?
Key Response
A lower-than-expected event rate reduces the statistical power to detect a significant treatment effect, increasing the risk of a Type II error. To mitigate this in HFpEF research, modern trials utilize 'clinical enrichment'—selecting patients with elevated natriuretic peptides (NT-proBNP), recent HF hospitalizations, or objective structural markers (left atrial enlargement) to ensure the cohort has a high enough event rate to demonstrate therapeutic efficacy.
As a reviewer, how would you evaluate the impact of 'competing risks' from non-cardiovascular comorbidities on the primary composite endpoint of the I-PRESERVE trial?
Key Response
In older HFpEF populations, non-cardiovascular death is a significant 'competing risk' that can obscure the potential benefit of a cardiac intervention. A critical reviewer would flag that if a large proportion of the study population dies from non-cardiac causes (cancer, pulmonary disease, etc.), the study may be underpowered to show a difference in cardiovascular-specific outcomes, even if the drug has a biological effect on the heart.
How do the I-PRESERVE results reconcile with the current 2022 AHA/ACC/HFSA guideline recommendations for the use of ARBs in HFpEF patients?
Key Response
Current guidelines provide a Class 2b (Weak) recommendation for ARBs in HFpEF to potentially reduce hospitalizations, but this is primarily based on the CHARM-Preserved trial and TOPCAT (for spironolactone). I-PRESERVE reinforces the guideline stance that ARBs are not recommended for mortality reduction in this population (Level of Evidence: B-R). The guidelines prioritize SGLT2 inhibitors (Class 1) and suggest ARBs mainly for their role in managing hypertension (Class 1) rather than as a primary HFpEF treatment.
Clinical Landscape
Noteworthy Related Trials
CHARM-Preserved Trial
Tested
Candesartan
Population
Patients with symptomatic heart failure and LVEF >40%
Comparator
Placebo
Endpoint
Composite of CV death or hospital admission for worsening HF
TOPCAT Trial
Tested
Spironolactone
Population
Patients with symptomatic heart failure and LVEF >45%
Comparator
Placebo
Endpoint
Composite of death from CV causes, aborted cardiac arrest, or hospitalization for heart failure
PARAGON-HF Trial
Tested
Sacubitril/valsartan
Population
Patients with heart failure and LVEF >45%
Comparator
Valsartan
Endpoint
Total hospitalizations for heart failure and death from cardiovascular causes
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis